AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
29/01/2026 – AB Science announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent relating to methods of treating metastatic castrate resistant prostate cancer (mCRPC)